Data / Public companies / Pharmaceutical preparations
Pharmaceutical preparations (SIC 2834): 561 companies that file annual reports with the SEC
561 companies that file annual reports with the SEC have the industry code SIC 2834 (Pharmaceutical preparations), in the data filed through September 30, 2026. 272 report revenue, a combined $619.76 billion, with a median of $44.2 million. 14.8% of the 493 that report net income show a profit. The largest by revenue is Johnson & Johnson ($94.19 billion).
SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.
- SIC code
- 2834
- SEC industry title
- Pharmaceutical Preparations
- Division
- Manufacturing
- Companies with an annual report in the data
- 561
- Companies that report revenue
- 272
- Combined revenue
- $619.76 billion
- Median revenue
- $44.2 million
- Reported a net profit
- 73 of 493 (14.8%)
- Combined total assets
- $1.48 trillion
- Large accelerated filers
- 116
- Newest annual report filed
- September 30, 2026
Largest by revenue
Latest fiscal year, from each company's annual report. Each name links to the company's page.
| Company | Business address | Revenue | Net income | Total assets | Revenue change |
|---|---|---|---|---|---|
| Johnson & Johnson | New Brunswick, NJ | $94.19 billion | $26.80 billion | $199.21 billion | 6% |
| Eli Lilly & Co | Indianapolis, IN | $65.18 billion | $20.64 billion | $112.48 billion | 44.7% |
| Merck & Co., Inc. | Rahway, NJ | $65.01 billion | $18.25 billion | $136.87 billion | 1.3% |
| Pfizer Inc | New York, NY | $62.58 billion | $7.77 billion | $208.16 billion | -1.6% |
| Abbvie Inc. | North Chicago, IL | $61.16 billion | $4.23 billion | $133.96 billion | 8.6% |
| Bristol Myers Squibb Co | Princeton, NJ | $48.19 billion | $7.05 billion | $90.04 billion | -0.2% |
| Abbott Laboratories | Abbott Park, IL | $44.33 billion | $6.52 billion | $86.71 billion | 5.7% |
| Universe Pharmaceuticals Inc | Ji'an, Jiangxi, China | $17.86 billion | $-3,672,055,000 | $69.30 billion | -22.4% |
| Teva Pharmaceutical Industries LTD | Tel Aviv | $17.26 billion | $1.41 billion | $40.75 billion | 4.3% |
| Regeneron Pharmaceuticals, Inc. | Tarrytown, NY | $14.34 billion | $4.50 billion | $40.56 billion | 1% |
| Viatris Inc | Canonsburg, PA | $14.30 billion | $-3,514,900,000 | $37.19 billion | -3% |
| Vertex Pharmaceuticals Inc / Ma | Boston, MA | $12.00 billion | $3.95 billion | $25.64 billion | 8.9% |
| Bausch Health Companies Inc. | Quebec, Canada | $10.27 billion | $157 million | $26.37 billion | 6.7% |
| Zoetis Inc. | Parsippany, NJ | $9.47 billion | $2.67 billion | $15.47 billion | 2.3% |
| Organon & Co. | Jersey City, NJ | $6.22 billion | $187 million | $12.87 billion | -2.9% |
| Beone Medicines LTD. | Basel | $5.34 billion | $286.9 million | $8.19 billion | 40.2% |
| Elanco Animal Health Inc | Indianapolis, IN | $4.72 billion | $-232,000,000 | $13.36 billion | 6.2% |
| Jazz Pharmaceuticals PLC | Dublin | $4.27 billion | $-356,148,000 | $11.66 billion | 4.9% |
| Perrigo Co PLC | Dublin 2, Ireland | $4.25 billion | $-1,425,400,000 | $8.54 billion | -2.8% |
| Alnylam Pharmaceuticals, Inc. | Cambridge, MA | $3.71 billion | $313.7 million | $4.97 billion | 65.2% |
| Biomarin Pharmaceutical Inc | Novato, CA | $3.22 billion | $348.9 million | $7.59 billion | 12.9% |
| United Therapeutics Corp | Silver Spring, MD | $3.18 billion | $1.33 billion | $7.88 billion | 10.6% |
| Amneal Pharmaceuticals, Inc. | $3.02 billion | $72.1 million | $3.68 billion | 8% | |
| Royalty Pharma PLC | New York, NY | $2.38 billion | $770.9 million | $19.62 billion | 5.1% |
| Sarepta Therapeutics, Inc. | Cambridge, MA | $2.20 billion | $-713,410,000 | $3.35 billion | 15.6% |
Largest by total assets
| Company | Business address | Revenue | Net income | Total assets |
|---|---|---|---|---|
| Pfizer Inc | New York, NY | $62.58 billion | $7.77 billion | $208.16 billion |
| Johnson & Johnson | New Brunswick, NJ | $94.19 billion | $26.80 billion | $199.21 billion |
| Merck & Co., Inc. | Rahway, NJ | $65.01 billion | $18.25 billion | $136.87 billion |
| Abbvie Inc. | North Chicago, IL | $61.16 billion | $4.23 billion | $133.96 billion |
| Eli Lilly & Co | Indianapolis, IN | $65.18 billion | $20.64 billion | $112.48 billion |
| Bristol Myers Squibb Co | Princeton, NJ | $48.19 billion | $7.05 billion | $90.04 billion |
| Abbott Laboratories | Abbott Park, IL | $44.33 billion | $6.52 billion | $86.71 billion |
| Universe Pharmaceuticals Inc | Ji'an, Jiangxi, China | $17.86 billion | $-3,672,055,000 | $69.30 billion |
| Teva Pharmaceutical Industries LTD | Tel Aviv | $17.26 billion | $1.41 billion | $40.75 billion |
| Regeneron Pharmaceuticals, Inc. | Tarrytown, NY | $14.34 billion | $4.50 billion | $40.56 billion |
| Viatris Inc | Canonsburg, PA | $14.30 billion | $-3,514,900,000 | $37.19 billion |
| Bausch Health Companies Inc. | Quebec, Canada | $10.27 billion | $157 million | $26.37 billion |
| Vertex Pharmaceuticals Inc / Ma | Boston, MA | $12.00 billion | $3.95 billion | $25.64 billion |
| Royalty Pharma PLC | New York, NY | $2.38 billion | $770.9 million | $19.62 billion |
| Zoetis Inc. | Parsippany, NJ | $9.47 billion | $2.67 billion | $15.47 billion |
Companies by size of revenue
Companies that report revenue, by the revenue in their latest annual report.
| Revenue | Companies | Share |
|---|---|---|
| Under $10 million | 98 | 36% |
| $10 million to $100 million | 71 | 26.1% |
| $100 million to $1 billion | 70 | 25.7% |
| $1 billion to $10 billion | 20 | 7.4% |
| $10 billion and over | 13 | 4.8% |
States with the most companies
By state of the business address.
| State | Companies | Share | Combined revenue |
|---|---|---|---|
| California | 126 | 22.5% | $15.21 billion |
| Massachusetts | 74 | 13.2% | $22.35 billion |
| New Jersey | 41 | 7.3% | $228.38 billion |
| New York | 35 | 6.2% | $82.25 billion |
| Florida | 31 | 5.5% | $1.37 billion |
| Maryland | 21 | 3.7% | $4.81 billion |
| Texas | 21 | 3.7% | $62.5 million |
| Pennsylvania | 19 | 3.4% | $16.19 billion |
| Connecticut | 9 | 1.6% | $613.1 million |
| Illinois | 8 | 1.4% | $105.98 billion |
| Washington | 7 | 1.2% | $6.9 million |
| Minnesota | 5 | 0.9% | $1.15 billion |
| Nevada | 5 | 0.9% | $38,278 |
| Colorado | 4 | 0.7% | $57.6 million |
| Delaware | 4 | 0.7% | $119.3 million |
Newest annual reports
By the date the company filed its latest annual report with the SEC.
| Company | Filed | Fiscal year ended | Form | Revenue |
|---|---|---|---|---|
| Radiopharm Theranostics LTD | September 30, 2026 | June 30, 2026 | 20-F | Not listed |
| Palatin Technologies Inc | September 28, 2026 | June 30, 2026 | 10-K | $13.2 million |
| Nanoviricides, Inc. | September 28, 2026 | June 30, 2026 | 10-K | Not listed |
| Lite Strategy, Inc. | September 28, 2026 | June 30, 2026 | 10-K | Not listed |
| Incannex Healthcare Inc. | September 25, 2026 | June 30, 2026 | 10-K | $0 |
| Propanc Biopharma, Inc. | September 25, 2026 | June 30, 2026 | 10-K | Not listed |
| Integrated Biopharma Inc | September 25, 2026 | June 30, 2026 | 10-K | $43.9 million |
| Immuron LTD | September 24, 2026 | June 30, 2026 | 20-F | Not listed |
| Rezolute, Inc. | September 24, 2026 | June 30, 2026 | 10-K | Not listed |
| Aytu Biopharma, Inc | September 22, 2026 | June 30, 2026 | 10-K | $57.6 million |
| Anaptysbio, Inc | September 21, 2026 | June 30, 2026 | 10-KT | Not listed |
| Neuphoria Therapeutics Inc. | September 18, 2026 | June 30, 2026 | 10-K | $1.2 million |
Filer category
The SEC's size class for the company when it filed.
| Category | Companies | Share |
|---|---|---|
| Non-accelerated filer | 402 | 71.7% |
| Large accelerated filer | 116 | 20.7% |
| Accelerated filer | 37 | 6.6% |
Updated September 30, 2026. Read from SEC Financial Statement Data Sets (sec.gov). Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.